Show simple item record Gángó, Ambrus Mózes, Réka Boha Z Kajtár, Béla Tímár, Botond Király, Péter Attila Kiss, Richárd Fesus V Nagy, Noémi Demeter, Judit Korosmezey G Borbényi, Zita Marton, Imelda Szoke A Masszi, Tamás Farkas, Péter Várkonyi, Judit Plander M Posfai E Egyed, Miklós Pal K Radvanyi G Hamed A Csomor, Judit Matolcsy, András Alpár, Donát Bödör, Csaba 2018-10-17T07:29:34Z 2018-10-17T07:29:34Z 2018
dc.identifier 85039962524
dc.identifier.citation pagination=42-48; journalVolume=65; journalTitle=LEUKEMIA RESEARCH;
dc.identifier.uri doi:10.1016/j.leukres.2017.12.005
dc.description.abstract BACKGROUND: Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized by frequent mutations of driver genes including JAK2, CALR and MPL. While the influence of JAK2 V617F mutant allele burden on the clinical phenotype of MPN patients is well-described, the impact of CALR mutant allele burden on clinical features needs further investigation. PATIENTS AND METHODS: Quantitative assessment of JAK2 and CALR mutations was performed on diagnostic DNA samples from 425 essential thrombocythemia (ET) and 227 primary myelofibrosis patients using real-time quantitative PCR and fragment length analysis. Characterization of CALR mutations and detection of MPL mutations were performed by Sanger sequencing. RESULTS: Twelve novel CALR mutations have been identified. ET patients with CALR(mut) load exceeding the median value exhibited lower hemoglobin values (12.0 vs. 13.6g/dL), higher LDH levels (510 vs. 351 IU/L) and higher rate of myelofibrotic transformation (19% vs. 5%). The CALR(mut) load was higher among ET patients presenting with splenomegaly compared to those without splenomegaly (50.0% vs. 43.5%). CONCLUSION: Our study confirms the clinical significance of driver mutational status and JAK2(mut) load in MPNs; in addition, unravels a novel clinical association between high CALR(mut) load and a more proliferative phenotype in ET.
dc.relation.ispartof urn:issn:0145-2126
dc.title Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
dc.type Journal Article 2018-09-01T10:30:54Z
dc.language.rfc3066 en
dc.identifier.mtmt 3312155
dc.identifier.wos 000425507100008
dc.identifier.pubmed 29306106
dc.contributor.department SE/AOK/K/III. Sz. Belgyógyászati Klinika
dc.contributor.department SE/AOK/K/II. Sz. Belgyógyászati Klinika
dc.contributor.department SE/AOK/K/I. Sz. Belgyógyászati Klinika
dc.contributor.department SE/AOK/I/I. Sz. Patológiai és Kísérleti Rákkutató Intézet
dc.contributor.institution Semmelweis Egyetem

Files in this item



This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account